---
pmid: '23845444'
title: Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive
  breast cancer.
authors:
- Vaillant F
- Merino D
- Lee L
- Breslin K
- Pal B
- Ritchie ME
- Smyth GK
- Christie M
- Phillipson LJ
- Burns CJ
- Mann GB
- Visvader JE
- Lindeman GJ
journal: Cancer Cell
year: '2013'
full_text_available: false
doi: 10.1016/j.ccr.2013.06.002
---

# Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer.
**Authors:** Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, Smyth GK, Christie M, Phillipson LJ, Burns CJ, Mann GB, Visvader JE, Lindeman GJ
**Journal:** Cancer Cell (2013)
**DOI:** [10.1016/j.ccr.2013.06.002](https://doi.org/10.1016/j.ccr.2013.06.002)

## Abstract

1. Cancer Cell. 2013 Jul 8;24(1):120-9. doi: 10.1016/j.ccr.2013.06.002.

Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive 
breast cancer.

Vaillant F(1), Merino D, Lee L, Breslin K, Pal B, Ritchie ME, Smyth GK, Christie 
M, Phillipson LJ, Burns CJ, Mann GB, Visvader JE, Lindeman GJ.

Author information:
(1)ACRF Stem Cells and Cancer Division, The Walter and Eliza Hall Institute of 
Medical Research, Parkville, VIC 3052, Australia.

Comment in
    Breast Cancer Res. 2013;15(5):317. doi: 10.1186/bcr3568.

The prosurvival protein BCL-2 is frequently overexpressed in estrogen receptor 
(ER)-positive breast cancer. We have generated ER-positive primary breast tumor 
xenografts that recapitulate the primary tumors and demonstrate that the BH3 
mimetic ABT-737 markedly improves tumor response to the antiestrogen tamoxifen. 
Despite abundant BCL-XL expression, similar efficacy was observed with the BCL-2 
selective inhibitor ABT-199, revealing that BCL-2 is a crucial target. 
Unexpectedly, BH3 mimetics were found to counteract the side effect of 
tamoxifen-induced endometrial hyperplasia. Moreover, BH3 mimetics synergized 
with phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) 
inhibitors in eliciting apoptosis. Importantly, these two classes of inhibitor 
further enhanced tumor response in combination therapy with tamoxifen. 
Collectively, our findings provide a rationale for the clinical evaluation of 
BH3 mimetics in therapy for breast cancer.

Copyright Â© 2013 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.ccr.2013.06.002
PMID: 23845444 [Indexed for MEDLINE]
